BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20549133)

  • 1. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis.
    Ribeiro RA; Rohde LE; Polanczyk CA
    Arq Bras Cardiol; 2010 Aug; 95(2):230-7. PubMed ID: 20549133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
    Gong B; Li Z; Yat Wong PC
    J Cardiothorac Vasc Anesth; 2015 Dec; 29(6):1415-25. PubMed ID: 26275522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
    J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
    Landoni G; Biondi-Zoccai G; Greco M; Greco T; Bignami E; Morelli A; Guarracino F; Zangrillo A
    Crit Care Med; 2012 Feb; 40(2):634-46. PubMed ID: 21963578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
    Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
    Int J Cardiol; 2010 Feb; 138(3):281-9. PubMed ID: 18817994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis.
    Qiu J; Jia L; Hao Y; Huang S; Ma Y; Li X; Wang M; Mao Y
    Life Sci; 2017 Sep; 184():30-36. PubMed ID: 28689804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levosimendan in cardiology and intensive care medicine].
    Delle Karth G; Heinz G
    Wien Klin Wochenschr; 2004 Jan; 116(1-2):6-14. PubMed ID: 15030117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Shang G; Yang X; Song D; Ti Y; Shang Y; Wang Z; Tang M; Zhang Y; Zhang W; Zhong M
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):453-463. PubMed ID: 28597399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
    Unverzagt S; Wachsmuth L; Hirsch K; Thiele H; Buerke M; Haerting J; Werdan K; Prondzinsky R
    Cochrane Database Syst Rev; 2014 Jan; (1):CD009669. PubMed ID: 24385385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is levosimendan effective in paediatric heart failure and post-cardiac surgeries?
    Angadi U; Westrope C; Chowdhry MF
    Interact Cardiovasc Thorac Surg; 2013 Oct; 17(4):710-4. PubMed ID: 23832921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
    JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
    Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
    Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.